Filtered By:
Management: Food and Drug Administration (FDA)
Nutrition: Vitamins
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 34 results found since Jan 2013.
In the Raw: To Cook or Not to Cook?
Imagine never again savoring the smell of baking cakes or charbroiled steak.
Could you? Why would you?
Yet some people worldwide are turning away not only from meat and processed food, but also from cooking.
Welcome to the raw food diet.
As the Standard American Diet becomes more fat-laden, sugar-sated, and processed, the prevalence of metabolic disorders, obesity, type 2 diabetes, and cardiovascular disease (CVD) are soaring.
According to the Centers for Disease Control and Prevention (CDC), obesity now affects nearly 35 percent of the population of the United States, over 29 million people have been diagnosed with t...
Source: Healthy Living - The Huffington Post - August 4, 2016 Category: Consumer Health News Source Type: news
Oral anticoagulation in emergency department patients: high rates of off-label doses,no difference in bleeding rates
Patients with oral anticoagulation constitute an increasing proportion in the present medical routine.1 The approval of the first direct oral anticoagulant (DOAC) dabigatran by the U.S. food and drug administration in 2010 for the purpose of stroke prevention in patients with non-valvular atrial fibrillation revolutionized the therapy strategies of this entity since the Vitamin-K antagonists (VKA) warfarin, phenprocoumon and acenocoumarol had been the only available oral anticoagulants for decades.
Source: The American Journal of Medicine - October 23, 2019 Category: General Medicine Authors: Corinne M. Eschler, Bertram K. Woitok, Georg-Christian Funk, Philipp Walter, Volker Maier, Aristomenis K. Exadaktylos, Gregor Lindner Tags: Clinical Research Study Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
What the Science Says About the Health Benefits of Vitamins and Supplements
From multivitamins and melatonin to fiber and fish oil, Americans who are trying to boost their health and immunity have a plethora of supplements to choose from. An estimated 58% of U.S. adults ages 20 and over take dietary supplements, according to the U.S. Centers for Disease Control and Prevention, and the supplement industry is valued at more than $30 billion a year. Supplement use has been growing rapidly over the past few decades along with the wellness industry.
“The popular belief is that a supplement is going to be helpful for promoting health,” says Fang Fang Zhang, a professor at Tufts University&rs...
Source: TIME: Health - April 28, 2022 Category: Consumer Health News Authors: Sandeep Ravindran Tags: Uncategorized Diet & Nutrition healthscienceclimate Source Type: news
